The burden of end-stage renal disease in Khartoum, Sudan: cost of illness study

被引:0
|
作者
Hajomer, Hiba Ali [1 ]
Elkhidir, Osama Ahmed [1 ]
Elawad, Shaima Omer [2 ,4 ]
Elniema, Ola Hatim [2 ]
Khalid, Mustafa Khalid [2 ]
Altayib, Lina S. [2 ]
Abdalla, Ibrahim Ahmed [2 ]
Mahmoud, Tahani Amin [3 ]
机构
[1] Natl Univ Khartoum, Community Med Dept, Khartoum, Sudan
[2] Univ Khartoum, Fac Med, Khartoum, Sudan
[3] Natl Univ Khartoum, Khartoum, Sudan
[4] Univ Khartoum, Fac Med, Khartoum 11115, Sudan
关键词
Cost of illness; health economics; end-stage renal disease; chronic kidney disease; burden of kidney disease; I10; I1; I; I11; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS; HYPERTENSION;
D O I
10.1080/13696998.2024.2320506
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background and purposeThe incidence of end-stage renal disease (ESRD) in Sudan is increasing, affecting the economic status of patients, caregivers and society. This study aimed to measure ESRD's costs, including direct and morbidity indirect expenditures, and to investigate any associated factors and financial consequences.Materials and methodsThis cross-sectional study used a standardized questionnaire to collect data from 150 ESRD patients who had been receiving dialysis for at least one year before the time of data collection at 13 specialized renal centres in Khartoum state. Data about sociodemographic, clinical, and economic factors were gathered, and their relationship to the cost of ESRD was examined using both bivariate (Man Whitney test, Kruskal Wallis test and Spearman correlation) and multivariate analytical procedures (multivariate linear regression).ResultsThis study reported a median direct per capita ESRD cost of 38 600 SDG ($1 723.2 PPP) annually with an interquartile range of 69 319.3 SDG ($3 094.6 PPP). The median morbidity indirect cost was estimated to be 0.0 +/- 3 352 SDG ($ 0.0 +/- 149.6 PPP) per annum. In 28.8% of cases, the patients were their family's primary income earner and over 85% were covered by medical insurance. Our study found that none of the study variables were significantly associated with the total cost of ESRD.Conclusion and limitationsOur findings point out considerable direct out-of-pocket expenses and productivity losses for patients and their households. However, these results should be carefully applied for comparison between the different countries due to differences in the cost of medical interventions and insurance coverage. Further longitudinal studies and studies on health finance and insurance policies are recommended. As medical care costs continue to rise in Sudan, this study aimed to estimate direct and indirect costs associated with end-stage renal disease (ESRD) from the patient's perspective. Accurate information on the cost of illness (COI) helps policymakers prioritize healthcare services and resources, optimize public well-being, and determine health policy effectiveness. Future research should include a longitudinal design and understand ESRD costs from caregivers' and healthcare providers' perspectives.
引用
收藏
页码:455 / 462
页数:8
相关论文
共 50 条
  • [41] A REVIEW OF COST OF ILLNESS STUDIES IN PATIENTS WITH END STAGE RENAL DISEASE
    Paczkowski, R.
    Norrbacka, K.
    Van Brunt, K.
    Kennedy-Martin, T.
    VALUE IN HEALTH, 2014, 17 (07) : A468 - A468
  • [42] Putting an end to end-stage renal disease
    Setness, PA
    POSTGRADUATE MEDICINE, 2000, 108 (01) : 11 - 11
  • [43] Cost calculations during "dire straits": a cost-of-illness analysis of regular hemodialysis for end-stage renal disease in Greece
    Naoum, Panagiota
    Topkaroglou, Ioannis
    Kitsonis, Dimitrios
    Skroumpelos, Anastasios
    Athanasakis, Kostas
    Iatrou, Christos
    Boletis, John
    Kyriopoulos, John
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2016, 39 (02): : 87 - 89
  • [44] Cost-Effectiveness Analysis of Treatment for End-Stage Renal Disease
    Asgeirsdottir, Tinna Laufey
    Asmundsdottir, Gyoa
    Heimisdottir, Maria
    Jonsson, Eirikur
    Palsson, Runolfur
    LAEKNABLADID, 2009, 95 (11): : 747 - 753
  • [45] Modelling the Cost-Effectiveness of Delaying End-Stage Renal Disease
    de Vries, Eline F.
    Rabelink, Ton J.
    van den Hout, Wilbert B.
    NEPHRON, 2016, 133 (02) : 89 - 97
  • [46] Potential cost savings of erythropoietin administration in end-stage renal disease
    Hynes, DM
    Stroupe, KT
    Greer, JW
    Reda, DJ
    Frankenfield, DL
    Kaufman, JS
    Henderson, WG
    Owen, WF
    Rocco, MV
    Wish, JB
    Kang, J
    Feussner, JR
    AMERICAN JOURNAL OF MEDICINE, 2002, 112 (03): : 169 - 175
  • [48] END-STAGE RENAL-DISEASE - BETTER TREATMENT AT LOWER COST
    BURTON, BT
    ANNALS OF INTERNAL MEDICINE, 1978, 88 (04) : 567 - 568
  • [49] Incidence, prevalence, treatment and cost of end-stage renal disease in Indonesia
    Prodjosudjadi, Wiguno
    ETHNICITY & DISEASE, 2006, 16 (02) : 14 - 16
  • [50] Exploring the High Burden of Cardiovascular Disease Among Patients with End-Stage Renal Disease
    Liakopoulos, Vassilios
    Georgianos, Panagiotis I.
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (01) : 1 - 3